BioSpace News Archive

Immorna today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a Phase 1/2 multi-center study of JCXH-221.

Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease, announced key additions to its senior management team.

BioArctic AB’s partner Eisai will present the efficacy, safety and biomarker results from the Phase 3 confirmatory Clarity AD clinical trial for lecanemab, at the 15th Clinical Trials on Alzheimer’s Disease conference, held in San Francisco, CA and virtually from November 29 to December 2.

Using a special type of MRI, researchers have uncovered brain changes in patients up to six months after they recovered from COVID-19, according to a study being presented next week at the annual meeting of the Radiological Society of North America.

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2022.

XNK Therapeutics AB said the company would continue its partnership with the Karolinska Cell Therapy Center’s production unit Vecura under the lead of Pontus Blomberg and Veronique Chotteau’s group in Cell Technology from the Swedish Royal Institute of Technology as part of a collaboration within The Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO.

Ainos, Inc. announced that it has published preclinical data demonstrating the potential of its low-dose oral interferon-alpha formulation, VELDONA®, as treatment candidates for the two most common medical conditions for dogs and cats.

ImmunoGen, Inc. today announced that Daniel Char, JD, has been appointed Senior Vice President and Chief Legal Officer.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Eliav Barr, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, is scheduled to participate in a virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, Dec. 1, 2022 at 9:40 a.m. ET.

Nordic Nanovector ASA desires to share more information with the Company’s shareholders about the proposed merger between the Company and APIM Therapeutics.